- /
- Supported exchanges
- / US
- / HYPMY.PINK
Hypera SA (HYPMY PINK) stock market data APIs
Hypera SA Financial Data Overview
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Hypera SA data using free add-ons & libraries
Get Hypera SA Fundamental Data
Hypera SA Fundamental data includes:
- Net Revenue: 7 699 M
- EBITDA: 1 954 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hypera SA News
New
Hypera SA (HYPMY) Q4 2025 Earnings Call Highlights: Record Cash Flow and Strategic Market Expansion
This article first appeared on GuruFocus. Sell-Out Growth: 6.8% in 2025, with 8.3% in Q3 and 7.4% in Q4. Net Revenue: BRL7.7 billion, a 3.4% increase from the previous year. Gross Margin: 59% for 202...
Scotiabank initiates Hypera stock with Sector Outperform rating
Investing.com - Scotiabank (TSX:BNS) initiated coverage on Hypera SA (BVMF:HYPE3) (OTC:HYPMY), a $3.17 billion market cap pharmaceutical company, with a Sector Outperform rating and a price target o...
Hypera SA (HYPMY) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges
Release Date: March 21, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hypera SA (HYPMY) achieved a 9% increase in sellout...
Hypera SA (HYPMY) Q3 2024 Earnings Call Highlights: Strong Sellout Growth and Strategic ...
Sellout Growth: 11% in Q3 2024, driven by normalization of demand for flu, respiratory pain, and fever products. Gross Margin: Maintained close to 60% despite lower revenue. Marketing Expenses: Increa...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.